Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00401440
Other study ID # 3-Chaudhuri
Secondary ID
Status Completed
Phase Phase 4
First received November 16, 2006
Last updated March 11, 2010
Start date January 2007
Est. completion date September 2008

Study information

Verified date December 2008
Source Nilratan Sircar Medical College
Contact n/a
Is FDA regulated No
Health authority India: Ministry of Health
Study type Interventional

Clinical Trial Summary

The hypothesis of the study is that the induction abortion interval time will be significantly shorter in the group receiving vaginal misoprostol every six hours in comparison to the group who are receiving vaginal misoprostol every twelve hours.


Description:

Objectives:

Misoprostol, a prostaglandin analogue, is principally used to prevent peptic ulcer disease induced by nonsteroidal anti-inflammatory agents .It has been shown to induce second trimester abortion .However , the optimal regimen has not been determined .Studies have used doses ranging 200- 800 microgram misoprostol at interval ranging from 3-12 hours.1,2,3,4,5 In our previous study we have compared intravaginal misoprostol with extra amniotic ethacridine lactate for second trimester MTP.6 In this study we have observed that misoprostol is highly effective( success rate 95%) for second trimester MTP with minimal side effects .& intravaginal misoprostol results in significantly shorter induction abortion interval in comparison to extra amniotic ethacridine lactate .Induction abortion interval in this study for misoprostol was 15.5 hours and the dosage of misoprostol was 400 microgram vaginally every 12 hours with a maximum of 4 doses .Success rate and induction abortion interval are the major factors of clinical importance for second trimester MTP . Our aim is to establish a dosage schedule of misoprostol which will result in high success rate in mid trimester MTP with further shortening of induction abortion interval Our study hypothesis is that using 400 microgram of vaginal misoprostol at six hour interval will result in significant shortening of induction abortion interval in comparison to 400 microgram vaginal misoprostol at 12 hour interval.

Methods - A prospective randomized comparative clinical trial will be conducted over 200 women.

Women attending the hospital for mid trimester MTP i.e. 12-20 weeks of pregnancy will be taken up for the study. Gestational age will be determined from LMP & per abdominal findings. Ultrasonography will be done in selected women where clinical finding is unreliable . All women will be examined for vital parameters and routine hematological and urine examination will be done. Randomization will be done using a table of random numbers .A written consent for inclusion in the study will be taken from all patients who will be included in the study.

In one group women will receive 400 microgram vaginal misoprostol tablet at interval of 12 hours with a maximum of four doses.

In other group women will receive 400 microgram vaginal misoprostol tablet at an interval of 6 hours with a maximum of four doses.

Failure of procedure in both groups will be defined as failed expulsion of fetus at 48 hours or as the occurrence of systemic adverse signs and symptoms severe enough to preclude the use of additional drugs.

The patient's vital signs will be monitored every four hours and the occurrence of signs and symptoms, such as fever, pain, vomiting, and diarrhea will be recorded. After expulsion of the fetus and placenta, check curettage will be done in every case. Completeness of abortion will be defined as expulsion of both placenta and fetus without operative assistance. The induction abortion interval will be defined as time from administration of 1st dose of Misoprostol to abortion of fetus. Hemorrhage will be defined as an estimated blood loss exceeding 500 ml or need to blood transfusion. Fever will be defined as rise of temperature 100.4˚ F or more occurring 24 hours or more after pregnancy termination.

The following parameters will be studied (1) Induction abortion interval (2) Completeness of procedure (3) Failure of abortion (4) side effects (5) cost per procedure.

Statistical analysis will be carried out with Epi Info statistical software.


Recruitment information / eligibility

Status Completed
Enrollment 185
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender Female
Age group 14 Years to 45 Years
Eligibility Inclusion Criteria:

- Women fulfilling indications of Medical Termination Of Pregnancy Act of India

- 12-20 weeks of pregnancy

Exclusion Criteria:

- Women with previous uterine surgery

- Contraindication of misoprostol use

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Misoprostol
400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
Misoprostol
400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses

Locations

Country Name City State
India Department of Gynae & Obstetrics, Nilratan Sircar Medical College , Kolkata Kolkata West Bengal

Sponsors (1)

Lead Sponsor Collaborator
Nilratan Sircar Medical College

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary induction abortion interval 48 hours Yes
Secondary Success rate 48 hours Yes
Secondary Side effects 48 hours Yes
Secondary complete expulsion of products of conception 72 hours No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02208596 - The Feasibility of Different Doses of Etomidate Admixed With Propofol in Induced Abortion: A Randomized, Double Blind Controlled Trial Phase 4
Completed NCT02412618 - Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation Phase 4
Completed NCT01842100 - To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy N/A
Completed NCT00540748 - Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful? N/A
Completed NCT03727308 - Study of Clinic-based Versus Self-use of Medical Abortion Pills
Completed NCT00482209 - Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation N/A
Recruiting NCT04242212 - Study of Clinic-based vs. Self-use of a Misoprostol-only Regimen for Induced Abortion
Completed NCT00621543 - Insertion of an Intrauterine Device (IUD) After Medical Abortion N/A
Recruiting NCT01636063 - Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks N/A
Completed NCT01173003 - Expansion Study of a Simplified Regimen of Medical Abortion Thru 63 Last Menstrual Period (LMP) in Tunisia N/A
Completed NCT05532085 - Assessment of Pain During an Abortion With Knowledge of the Predictive Factors of Pain.
Terminated NCT01776957 - Post Abortion IUD & Recurrent Abortion 2005-2006
Completed NCT01047748 - A Trial of Digoxin Before Second-Trimester Abortion N/A
Completed NCT00619658 - The Feasibility of Simplified Telephone Follow-up After Medical Abortion N/A
Completed NCT00324519 - Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester Phase 4
Completed NCT04181541 - Midlevel Versus Physician-provided Medical Abortion in the Second Trimester N/A
Completed NCT00286208 - Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation N/A
Completed NCT01085825 - Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion N/A